A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC) Meeting Abstract
| Authors: | O'Cearbhaill, R. E.; Wolfer, A.; Disilvestro, P.; O'Malley, D. M.; Sabbatini, P.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M.; Ryan, A.; Venhaus, R. R.; Bryan, J. K.; Wong, P.; Homicsko, K.; Kandalaft, L.; Rusakiewicz, S.; Harari, A.; Monk, B. J.; Coukos, G. |
| Abstract Title: | A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy285.153 |
| Language: | English |
| ACCESSION: | WOS:000459277302127 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy285.153 |
| Notes: | Meeting Abstract: 945P -- Appears on page viii337 of the abstract book -- Source: Wos |
